NIH. Cancer statistics. 2023. Available from: https://seer.cancer.gov/statistics/.

Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, et al. Effect of screening on ovarian cancer mortality: the prostate, lung, colorectal and ovarian (PLCO) cancer screening randomized controlled trial. JAMA. 2011;305(22):2295–303.

Article  CAS  PubMed  Google Scholar 

Menon U, Gentry-Maharaj A, Burnell M, Singh N, Ryan A, Karpinskyj C, et al. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2021;397(10290):2182–93.

Article  PubMed  PubMed Central  Google Scholar 

Henderson JT, Webber EM, Sawaya GF. Screening for ovarian cancer: updated evidence report and systematic review for the US preventive services task force. JAMA. 2018;319(6):595–606.

Article  PubMed  Google Scholar 

Walker JL, Powell CB, Chen LM, Carter J, Bae Jump VL, Parker LP, et al. Society of gynecologic oncology recommendations for the prevention of ovarian cancer. Cancer. 2015;121(13):2108–20.

Article  PubMed  Google Scholar 

Karlsson T, Johansson T, Hoglund J, Ek WE, Johansson A. Time-dependent effects of oral contraceptive use on breast, ovarian, and endometrial cancers. Cancer Res. 2021;81(4):1153–62.

Article  CAS  PubMed  Google Scholar 

Havrilesky LJ, Gierisch JM, Moorman PG, Coeytaux RR, Urrutia RP, Lowery WJ, et al. Oral contraceptive use for the primary prevention of ovarian cancer. Evid Rep Technol Assess (Full Rep). 2013;212:1–514.

Google Scholar 

Shih IM, Wang Y, Wang TL. The origin of ovarian cancer species and precancerous landscape. Am J Pathol. 2021;191(1):26–39.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Piek JM, Verheijen RH, Kenemans P, Massuger LF, Bulten H, van Diest PJ. BRCA1/2-related ovarian cancers are of tubal origin: a hypothesis. Gynecol Oncol. 2003;90(2):491.

Article  PubMed  Google Scholar 

Vang R, Shih Ie M, Kurman RJ. Fallopian tube precursors of ovarian low- and high-grade serous neoplasms. Histopathology. 2013;62(1):44–58.

Article  PubMed  Google Scholar 

Gockley AA, Elias KM. Fallopian tube tumorigenesis and clinical implications for ovarian cancer risk-reduction. Cancer Treat Rev. 2018;69:66–71.

Article  PubMed  Google Scholar 

Michels KA, Pfeiffer RM, Brinton LA, Trabert B. Modification of the associations between duration of oral contraceptive use and ovarian, endometrial, breast, and colorectal cancers. JAMA Oncol. 2018;4(4):516–21.

Article  PubMed  PubMed Central  Google Scholar 

Gadducci A, Cosio S, Fruzzetti F. Estro-progestin contraceptives and risk of cervical cancer: a debated issue. Anticancer Res. 2020;40(11):5995–6002.

Article  CAS  PubMed  Google Scholar 

Del Pup L, Codacci-Pisanelli G, Peccatori F. Breast cancer risk of hormonal contraception: counselling considering new evidence. Crit Rev Oncol Hematol. 2019;137:123–30.

Article  PubMed  Google Scholar 

Nagykalnai T, Landherr L. Oral contraception and the risk of breast cancer. Review of the literature. Magy Onkol. 2018;62(4):258–63.

PubMed  Google Scholar 

Park J, Huang D, Chang YJ, Lim MC, Myung SK. Oral contraceptives and risk of breast cancer and ovarian cancer in women with a BRCA1 or BRCA2 mutation: a meta-analysis of observational studies. Carcinogenesis. 2022;43(3):231–42.

Article  CAS  PubMed  Google Scholar 

Pragout D, Laurence V, Baffet H, Raccah-Tebeka B, Rousset-Jablonski C. Contraception and cancer: CNGOF contraception guidelines. Gynecol Obstet Fertil Senol. 2018;46(12):834–44.

CAS  PubMed  Google Scholar 

Natanzon Y, Goode EL, Cunningham JM. Epigenetics in ovarian cancer. Semin Cancer Biol. 2018;51:160–9.

Article  CAS  PubMed  Google Scholar 

Munoz-Galvan S, Carnero A. Leveraging genomics, transcriptomics, and epigenomics to understand the biology and chemoresistance of ovarian cancer. Cancers (Basel). 2021;13(16):4029.

Article  CAS  PubMed  Google Scholar 

Liu D, Zhang XX, Li MC, Cao CH, Wan DY, Xi BX, et al. C/EBPbeta enhances platinum resistance of ovarian cancer cells by reprogramming H3K79 methylation. Nat Commun. 2018;9(1):1739.

Article  PubMed  PubMed Central  Google Scholar 

Duffy DM, Ko C, Jo M, Brannstrom M, Curry TE. Ovulation: parallels with inflammatory processes. Endocr Rev. 2019;40(2):369–416.

Article  PubMed  Google Scholar 

Pal T, Akbari MR, Sun P, Lee JH, Fulp J, Thompson Z, et al. Frequency of mutations in mismatch repair genes in a population-based study of women with ovarian cancer. Br J Cancer. 2012;107(10):1783–90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017;14(1):9–32.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Troisi R, Bjorge T, Gissler M, Grotmol T, Kitahara CM, Myrtveit Saether SM, et al. The role of pregnancy, perinatal factors and hormones in maternal cancer risk: a review of the evidence. J Intern Med. 2018;283(5):430–45.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Adami HO, Hsieh CC, Lambe M, Trichopoulos D, Leon D, Persson I, et al. Parity, age at first childbirth, and risk of ovarian cancer. Lancet. 1994;344(8932):1250–4.

Article  CAS  PubMed  Google Scholar 

Tsilidis KK, Allen NE, Key TJ, Dossus L, Lukanova A, Bakken K, et al. Oral contraceptive use and reproductive factors and risk of ovarian cancer in the European Prospective Investigation into Cancer and Nutrition. Br J Cancer. 2011;105(9):1436–42.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li DP, Du C, Zhang ZM, Li GX, Yu ZF, Wang X, et al. Breastfeeding and ovarian cancer risk: a systematic review and meta-analysis of 40 epidemiological studies. Asian Pac J Cancer Prev. 2014;15(12):4829–37.

Article  PubMed  Google Scholar 

Ramirez-de-Arellano A, Villegas-Pineda JC, Hernandez-Silva CD, Pereira-Suarez AL. The Relevant participation of prolactin in the genesis and progression of gynecological cancers. Front Endocrinol (Lausanne). 2021;12:747810.

Article  PubMed  Google Scholar 

Lurie G, Wilkens LR, Thompson PJ, McDuffie KE, Carney ME, Terada KY, et al. Combined oral contraceptive use and epithelial ovarian cancer risk: time-related effects. Epidemiology. 2008;19(2):237–43.

Article  PubMed  Google Scholar 

Fathalla MF. Incessant ovulation–a factor in ovarian neoplasia? Lancet. 1971;2(7716):163.

Article  CAS  PubMed  Google Scholar 

Fathalla MF. Incessant ovulation and ovarian cancer—a hypothesis re-visited. Facts Views Vis Obgyn. 2013;5(4):292–7.

CAS  PubMed  PubMed Central  Google Scholar 

Dubeau L. The cell of origin of ovarian epithelial tumours. Lancet Oncol. 2008;9(12):1191–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lauchlan SC. The secondary Mullerian system. Obstet Gynecol Surv. 1972;27(3):133–46.

Article  CAS  PubMed  Google Scholar 

Chene G, Lamblin G, Le Bail-Carval K, Chabert P, Bakrin N, Mellier G. Early preinvasive lesions in ovarian cancer. Biomed Res Int. 2014;2014:639252.

Article  PubMed  PubMed Central  Google Scholar 

Kurman RJ, Shih M. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol. 2010;34(3):433–43.

Article  PubMed  PubMed Central  Google Scholar 

Roh MH, Kindelberger D, Crum CP. Serous tubal intraepithelial carcinoma and the dominant ovarian mass: Clues to serous tumor origin? Am J Surg Pathol. 2009;33(3):376–83.

Article  PubMed  Google Scholar 

Ness RB, Cottreau C. Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst. 1999;91(17):1459–67.

Article  CAS  PubMed  Google Scholar 

Risch HA. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst. 1998;90(23):1774–86.

Article  CAS  PubMed  Google Scholar 

Han KH, Kim MK, Kim HS, Chung HH, Song YS. Protective effect of progesterone during pregnancy against ovarian cancer. J Cancer Prev. 2013;18(2):113–22.

Article